Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Has Consensus Price Target of $41.75

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $41.75.

AGIO has been the subject of a number of research reports. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Truist Financial decreased their price target on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday. HC Wainwright upped their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Bank of America increased their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC boosted its stake in Agios Pharmaceuticals by 12.0% during the second quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock worth $597,000 after buying an additional 1,724 shares during the last quarter. Engineers Gate Manager LP increased its stake in shares of Agios Pharmaceuticals by 86.4% in the 2nd quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company’s stock worth $2,001,000 after acquiring an additional 24,992 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $47,000. Squarepoint Ops LLC raised its holdings in shares of Agios Pharmaceuticals by 53.7% during the 2nd quarter. Squarepoint Ops LLC now owns 321,138 shares of the biopharmaceutical company’s stock worth $11,917,000 after acquiring an additional 112,250 shares during the period. Finally, Allworth Financial LP boosted its position in shares of Agios Pharmaceuticals by 2,798.5% during the 2nd quarter. Allworth Financial LP now owns 1,971 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 1,903 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $32.90 on Tuesday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -4.69 and a beta of 0.60. The stock has a 50 day moving average price of $33.95 and a 200 day moving average price of $32.33.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, analysts predict that Agios Pharmaceuticals will post -5.82 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.